Clarice Therapeutics initiated an oral lichen planus study targeting 35 to 40 patients, with a 16-week endpoint, and plans to file its next-generation oral program this quarter.
ACRS · Aclaris Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $3.50
- Open
- $3.53
- Day range
- $3.44–3.62
- 52-week closing range
- $2.41–6.54
- Average volume, 30 days
- 2.9M
- Short interest
- 11.6M · 7.3% of shares · 4.0 days
- Short volume, last session
- 57%
- Last earnings
- Oct 27, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Aclaris Therapeutics, Inc. reported that the Phase 2 ADMIRATION trial of bosakitug (ATI-045) did not achieve primary or secondary endpoints at Week 24; it also began the Phase 2b ALPHA trial of modzatinib (ATI-2138) in lichen planus.
ATI-052 produced positive Phase 1b results in atopic dermatitis and asthma, while Aclaris Therapeutics reported a $59.8 million net loss for the nine months ended September 30, 2026.
Aclaris reported a third-quarter 2026 net loss of $18.5 million, versus $14.6 million a year earlier, with $204.6 million in cash and marketable securities at September 30, 2026. October 2026 sales of stock and pre-funded warrants raised $50.0 million gross, and cash is expected to fund operations through the first half of 2029. Phase 1b trials of ATI-052 showed positive primary results in atopic dermatitis and asthma.
Aclaris Therapeutics entered into an underwriting agreement on October 27, 2026 to sell 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares. The offering price is $3.50 per share and $3.49999 per Pre-Funded Warrant. The company estimates net proceeds of approximately $46.7 million, with closing expected on October 28, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| FeNO reduction at day 29 | 40% | day 29 | — |
| mean absolute reduction in fractional exhaled nitric oxide (FeNO) | 59% | day 15 | — |
| placebo adjusted and absolute improvement in FEV1 | 200 | day 15 | — |
| placebo-adjusted EASI-50 | 78% | week 8 | — |
| placebo-adjusted mean change in EASI score | 45% | week 8 | — |
| placebo-adjusted mean improvement in itch (PP-NRS) | 43% | week 8 | — |
| % PP-NRS Reduction | 38% | D57 | — |
| % Reduction from Baseline in EASI | 58% | D57 | — |
| % Reduction in FeNO | 59% | D15 | — |
| 78% | 78% | baseline | — |
| ATI-052 (FEV1 <80% at BL) | 350 | Day 15 | — |
| EASI-50 | 78% | D57 | — |
| FeNO normalization | 58% | day 15 | — |
| FeNO reductions in the eosinophil <300 subgroup (T2-low) | 58% | day 15 | — |
| FeNO reductions in the eosinophil ≥300 subgroup (T2-high) | 60% | day 15 | — |
| Increase in FEV1 (FEV1 <80% at BL) | 350 | D15 | — |
| Mean change in EASI score in the active arm | 58% | day 57 | — |
| Mean change in EASI score in the placebo arm | 13% | day 57 | — |
| Mean decrease from baseline in FEV1 in the placebo arm | 140 | day 15 | — |
| Mean improvement in itch (PP-NRS) | 40% | week 4 | — |
| Mean reduction from baseline in FeNO | 40% | day 29 | — |
| Mean reduction from baseline in FeNO in the placebo arm | 15% | day 15 | — |
| Mean worsening in itch (PP-NRS) in the placebo arm | 5% | day 57 | — |
| Normalization in the lesional skin proteome | 95% | week 8 | — |
| Overall = 78% | 78% | Week 8 | — |
| Patients with mild-to-moderate asthma | 16 | Phase 1b POC Trial in Asthma | — |
| Patients with severe AD | 14 | Phase 1b POC Trial in AD | — |
| Patients with severe disease at baseline | 78% | baseline | — |
| Pbo-adjusted Mean pre-BD FEV1 change from baseline | 200 | Day 15 | — |
| Placebo (FEV1 <80% at BL) | -140 | Day 15 | — |
| placebo adjusted and absolute mean improvement in FEV1 | 200 | day 15 | — |
| Placebo-adjusted and absolute mean improvement in FEV1 | 200 | day 15 | — |
| Placebo-adjusted EASI-50 in patients with a baseline severity of vIGA 3 | 100% | day 57 | — |
| Placebo-adjusted EASI-50 in patients with a baseline severity of vIGA 4 | 71% | day 57 | — |
| Placebo-adjusted mean improvement of ≥4-points in itch (PP-NRS4) | 33% | day 57 | — |
| worsening in itch (PP-NRS) | 5% | day 57 | — |
| worsening of FEV1 | -140 | day 15 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACRS
this stock
Aclaris Therapeutics, Inc.
|
$555.14M | +16.3% | -58.2% | — | 7.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 25
Clarice Therapeutics initiated an oral lichen planus study targeting 35 to 40 patients, with a 16-week endpoint, and plans to file its next-generation oral program this quarter.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACRS | -12.5% | -8.6% | -19.4% | -11.8% | +16.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -7.1% | -2.3% | -13.7% | -6.6% | +11.3% |